<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66962">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02234115</url>
  </required_header>
  <id_info>
    <org_study_id>FP01C-13-001</org_study_id>
    <secondary_id>2013-001790-25</secondary_id>
    <nct_id>NCT02234115</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma</brief_title>
  <official_title>An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foresee Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QPS-Qualitix</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Foresee Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of
      subjects with advanced prostate carcinoma, when administered as two injections six months
      apart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, single-arm study conducted in 2 parts. Part I was
      established to provide a vanguard of the first 30 subjects who will have more frequent
      monitoring of their safety. If safety is established, the remainder of the subjects will be
      entered into the clinical study (i.e., Part II). All subjects will be males with advanced
      prostate carcinoma judged to be candidates for medical androgen ablation therapy, and all
      will receive two injections of LMIS 50 mg six-month apart in an unblinded fashion.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Leuprolide Mesylate (LMIS 50mg)</measure>
    <time_frame>336 days</time_frame>
    <description>The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (≤ 50 ng/dL) by Day 28 ± 1(day) following the first injection of LMIS 50 mg and the percentage of subjects with serum testosterone suppression (≤ 50 ng/dL) from Day 28 through Day 336 (remaining duration of the study).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-suppression excursions of serum testosterone</measure>
    <time_frame>336 days</time_frame>
    <description>The proportion of subjects exhibiting post-suppression excursions of serum testosterone to &gt;50 ng/dL, either through &quot;breakthrough&quot; (i.e., episodes unrelated to LMIS 50 mg dosing), or through the &quot;acute-on-chronic&quot; phenomenon (i.e., related to the second dose of LMIS 50 mg); Effect of LMIS 50 mg on serum PSA levels; and Effect of LMIS 50 mg on serum LH levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Leuprolide Mesylate (LMIS 50mg)</measure>
    <time_frame>Days 0, 1, 2, 3, 7, 14, 21, 28, 56, 84, 112, 140, 168, 169, 170, 171, 196, 224, 252,280, 308, 336</time_frame>
    <description>Plasma leuprolide concentrations (ng/mL) in PK population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of LMIS 50 mg</measure>
    <time_frame>336 days</time_frame>
    <description>Determining the safety and tolerability of LMIS 50 mg based on adverse events (AEs), local tolerability, vital signs, electrocardiograms (ECGs), and clinical parameters</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Leuprolide Mesylate 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Mesylate</intervention_name>
    <description>Subcutaneous injection of 50mg Leuprolide Mesylate</description>
    <arm_group_label>Leuprolide Mesylate 50mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males aged ≥ 18 years old

          2. Males with histologically confirmed carcinoma of the prostate

          3. Subjects who are judged by the attending physician and/or Principal Investigator to
             be a candidate for androgen ablation therapy

          4. Baseline morning serum testosterone level &gt; 150 ng/dL performed at Screening Visit

          5. Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 2

          6. Life expectancy of at least 18 months

          7. Laboratory values

               -  Absolute neutrophil count ≥ 1,500 cells/µL

               -  Platelets ≥ 100,000 cells/µL

               -  Hemoglobin ≥ 10 gm/dL

               -  Total bilirubin ≤ 1.5 × upper limit of normal (ULN)

               -  AST (SGOT) ≤ 2.5 × ULN

               -  ALT (SGPT) ≤ 2.5 × ULN

               -  Serum creatinine ≤ 1.5 mg/dL

               -  Lipid profile within acceptable range according to investigator's judgment

               -  HgbA1c within acceptable range according to investigator's judgment

               -  Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to
                  investigator's judgment

               -  Serum glucose within acceptable range according to investigator's judgement

               -  Urinalysis within normal range according to the investigator's judgment

          8. Agree to use male contraceptive methods during study trial

          9. Based on the Investigator's judgment, the ability to understand the nature of the
             study and any hazards of participation, and to communicate satisfactorily with the
             Investigator and to participate in, and to comply with, the requirements of the
             entire protocol

         10. All aspects of the protocol explained and written informed consent obtained

        Exclusion Criteria:

          -  Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen
             therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of
             carcinoma of the prostate. Radiation for pain control will be allowed during the
             study.

          -  Receipt of any vaccination (including influenza) within 4 weeks of Baseline

          -  History of blood donation within 2 months of Baseline

          -  History of anaphylaxis to any LH-RH analogues

          -  Receipt of any LHRH suppressive therapy within 6 months of Baseline

          -  Major surgery, including any prostatic surgery, within 4 weeks of Baseline

          -  History and concomitant clinical and radiographic evidence of central nervous
             system/spinal cord metastases. Subjects at risk for spinal cord compression will be
             excluded.

          -  Clinical evidence of active urinary tract obstruction and subjects at risk for
             urinary obstruction

          -  History of bilateral orchiectomy, adrenalectomy, or hypophysectomy

          -  History or presence of hypogonadism, or receipt of exogenous testosterone
             supplementation within 6 months of Baseline

          -  Clinically significant abnormal ECG and/or history of clinically significant
             cardiovascular disease as judged by the investigator

          -  History of drug and/or alcohol abuse within 6 months of Baseline

          -  Contraindication to leuprolide or an LHRH agonist as indicated on package labeling

          -  Use of 5-alpha reductase inhibitor within the last 6 months of Baseline

          -  History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well
             controlled diabetes mellitus Type II will be allowed

          -  Use of systemic corticosteroids at a dose &gt;10 mg/d or anti-androgens

          -  Use of any investigational agent within 4 weeks of Baseline

          -  Use of any over-the-counter (OTC) medication within 4 weeks of Baseline except for
             those listed in the permitted Concomitant Treatment section.

          -  Uncontrolled intercurrent illness that would jeopardize the subject's safety,
             interfere with the objectives of the protocol, or limit the subject's compliance with
             study requirements, as determined by the Investigator in consultation with the
             Sponsor
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Mao, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Foresee Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology Centers of Alabama</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Research Centers</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Research, LLC</name>
      <address>
        <city>SanDiego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Urologic Institute - Meridian</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdvanceMed Research</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Clinical Trials, LLC</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Urology Research Center</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Linz GmbH, Department of Urology</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Urologie und Andrologie, Landeskrankenhaus Salzburg (University hospital for Urology and Andrology)</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice Urologické oddělení</name>
      <address>
        <city>Praha</city>
        <state>Praha 4 - Krč</state>
        <zip>140 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Hradec Králové Urologická klinika</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Olomouc Urologická klinika</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum RWTH Aachen, Klinik für Urologie</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PI Hospital of Lithuanian University of Health Sciences, Kauno Klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PI Klaipėda University Hospital</name>
      <address>
        <city>Klaipėda</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PI Vilnius University Hospital, Santariškių Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne, Klinika Urologii</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSW w Warszawie, Klinika Urologii i Urologii Onkologicznej</name>
      <address>
        <city>Warzawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Układu Moczowego</name>
      <address>
        <city>Warzawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;DERMED&quot; Centrum Medyczne Sp. z o.o.</name>
      <address>
        <city>Łódź</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UROCENTRUM MILAB, s.r.o.</name>
      <address>
        <city>Prešov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultná nemocnica s poliklinikou Žilina Urológia</name>
      <address>
        <city>Žilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veteran General Hospital (VGHKS)</name>
      <address>
        <city>Kaohsiung City</city>
        <state>Pingtung</state>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital (CMUH)</name>
      <address>
        <city>Taichung City</city>
        <state>Taichung</state>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veteran General Hospital (VGHTC)</name>
      <address>
        <city>Taichung City</city>
        <state>Taichung</state>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital (NCKUH)</name>
      <address>
        <city>Tainan City</city>
        <state>Tainan</state>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital (NTUH)</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, LinKou (CGMH-LK)</name>
      <address>
        <city>Guishan Township</city>
        <state>Taoyuan County</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 18, 2015</lastchanged_date>
  <firstreceived_date>September 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Neoplasm Cancer Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
